Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma
Christina E. Wells, Srividya Bhaskara, Kristy R. Stengel, et al.
PLoS ONE (2013) Vol. 8, Iss. 7, pp. e68915-e68915
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg, Ricky W. Johnstone
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 9, pp. 673-691
Closed Access | Times Cited: 1379
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li, Edward Seto
Cold Spring Harbor Perspectives in Medicine (2016) Vol. 6, Iss. 10, pp. a026831-a026831
Open Access | Times Cited: 1044
Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing
Bin Liu, Siwei Chen, Anouk La Rose, et al.
Nucleic Acids Research (2019) Vol. 48, Iss. 2, pp. 517-532
Open Access | Times Cited: 292
SIRT 7 promotes genome integrity and modulates non‐homologous end joining DNA repair
Berta N. Vázquez, Joshua K. Thackray, Nicolás G. Simonet, et al.
The EMBO Journal (2016) Vol. 35, Iss. 14, pp. 1488-1503
Open Access | Times Cited: 251
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
Erika Héninger, Timothy Krueger, Joshua M. Lang
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 184
Targeting Class I Histone Deacetylases in a “Complex” Environment
Christopher J. Millard, Peter J. Watson, Louise Fairall, et al.
Trends in Pharmacological Sciences (2017) Vol. 38, Iss. 4, pp. 363-377
Closed Access | Times Cited: 160
The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair
Wynand P. Roos, Andrea Krumm
Nucleic Acids Research (2016), pp. gkw922-gkw922
Open Access | Times Cited: 127
Chromatin modifications and DNA repair: beyond double-strand breaks
Nealia C. House, Melissa R. Koch, Catherine H. Freudenreich
Frontiers in Genetics (2014) Vol. 5
Open Access | Times Cited: 119
Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases
Carla Felice, Amy Lewis, Alessandro Armuzzi, et al.
Alimentary Pharmacology & Therapeutics (2014) Vol. 41, Iss. 1, pp. 26-38
Open Access | Times Cited: 108
How do tumor cells respond to HDAC inhibition?
Andrea Newbold, Katrina J. Falkenberg, H. Miles Prince, et al.
FEBS Journal (2016) Vol. 283, Iss. 22, pp. 4032-4046
Open Access | Times Cited: 103
Hdac3 Interaction with p300 Histone Acetyltransferase Regulates the Oligodendrocyte and Astrocyte Lineage Fate Switch
Liguo Zhang, Xuelian He, Lei Liu, et al.
Developmental Cell (2016) Vol. 36, Iss. 3, pp. 316-330
Open Access | Times Cited: 102
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs
Yufeng Xiao, Jia Wang, Lisa Zhao, et al.
Chemical Communications (2020) Vol. 56, Iss. 68, pp. 9866-9869
Open Access | Times Cited: 91
A chemical probe toolbox for dissecting the cancer epigenome
Jake Shortt, Christopher J. Ott, Ricky W. Johnstone, et al.
Nature reviews. Cancer (2017) Vol. 17, Iss. 3, pp. 160-183
Closed Access | Times Cited: 90
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives
Haitao Qin, Huan‐Qiu Li, Feng Liu
Expert Opinion on Therapeutic Patents (2016) Vol. 27, Iss. 5, pp. 621-636
Closed Access | Times Cited: 88
The application of histone deacetylases inhibitors in glioblastoma
Rui Chen, Mengxian Zhang, Yangmei Zhou, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 86
Clinical advances in targeting epigenetics for cancer therapy
Shengrui Feng, Daniel D. De Carvalho
FEBS Journal (2021) Vol. 289, Iss. 5, pp. 1214-1239
Open Access | Times Cited: 72
Hypertranscription and replication stress in cancer
Akhil Bowry, Richard D. Kelly, Eva Petermann
Trends in cancer (2021) Vol. 7, Iss. 9, pp. 863-877
Open Access | Times Cited: 57
Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells
Joshua P. Smalley, India M. Baker, Wiktoria A. Pytel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5642-5659
Open Access | Times Cited: 56
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Martina Korfei, Poornima Mahavadi, Andreas Guenther
Cells (2022) Vol. 11, Iss. 10, pp. 1626-1626
Open Access | Times Cited: 45
Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue
Gavin Rumbaugh, Stephanie E Daws, Emin D. Ozkan, et al.
Neuropsychopharmacology (2015) Vol. 40, Iss. 10, pp. 2307-2316
Open Access | Times Cited: 79
Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances
Huanling Wu, L. Jeffrey Medeiros, Ken H. Young
Blood Reviews (2017) Vol. 32, Iss. 1, pp. 8-28
Closed Access | Times Cited: 73
Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.
Madeline Wong, Chun Guo, Jinsong Zhang
PubMed (2014) Vol. 2, Iss. 3, pp. 169-87
Closed Access | Times Cited: 70
Emerging approaches for histone deacetylase inhibitor drug discovery
Clemens Zwergel, Sérgio Valente, Claus Jacob, et al.
Expert Opinion on Drug Discovery (2015) Vol. 10, Iss. 6, pp. 599-613
Closed Access | Times Cited: 69
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression
Manuela Terranova-Barberio, Maria Serena Roca, Andrea Ilaria Zotti, et al.
Oncotarget (2015) Vol. 7, Iss. 7, pp. 7715-7731
Open Access | Times Cited: 66
HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches
Nilanjan Adhikari, Sk. Abdul Amin, Prakruti Trivedi, et al.
European Journal of Medicinal Chemistry (2018) Vol. 157, pp. 1127-1142
Closed Access | Times Cited: 62
Page 1 - Next Page

Scroll to top